To strengthen supply chains and alleviate drug shortages, Antheia (NSF-1758423) develops a synthetic biology platform that uses engineered yeast cells to produce pharmaceutical ingredients in weeks instead of years. The company recently raised $56 million. Article via SynBioBeta.